Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
Live moderated video webcast discussion with N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer on Tuesday, November 16th at 11:00 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the...
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
- Dr. Lemere is a renowned translational researcher focused on understanding, preventing, and treating Alzheimer's disease - Company continues to advance evaluation of Trappsol® Cyclo™ toward Phase 2 study in Alzheimer's disease with investigational new...
Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
Company engaged in ongoing initiatives to help raise awareness and provide information on research and support for patients and families GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing...
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM)
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab
Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President of Medical Affairs to participate in a Moderated round-table discussion with academics and industrial experts on October 11, 2021 at 4:30 PM (CET) / 10:30 AM (EST) GAINESVILLE, Fla. - Cyclo...
Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer
- Dr. Kjems is a leading global physician scientist with a proven pharma track record of drug development across multiple therapeutic areas, including chronic indications, oncology and rare diseases - - Gerald F. Cox, MD, PhD will continue offering clinical...
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
- Live webcast presentation on Wednesday, September 22nd at 10:45 AM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through...
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
- Solid clinical and operational execution demonstrated with advancement of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with commencement of pivotal study (TransportNPC™) and start of commercial-scale manufacturing - Progression of Phase...
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
- Data seen to-date in the ongoing Phase 1 extension study provide additional support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1 ("NPC")- Favorable safety...